gilead glp-1 May 4, 2025: New study suggests more adverse events associated with compounded GLP-1s than standard formulations – Partnership for Safe Medicines 1 journey with Side Effect Relief Frontiers | GLP-1 receptor agonists

Clinical Evidence for Non-Diabetic Weight Loss The STEP trials, which enrolled predominantly non-diabetic participants, demonstrated that semaglutide produces average weight loss of 1022% of body weight over 68 weeks, depending on dose level

Subsequently, leveraging the superpopulation label and PCs of the 1000 Genome individuals, we train a K -nearest neighbors model to assign genetic ancestry labels to each ATLAS individual

Makary said in a statement

So I think there are so many things that you can learn from this, and of course it can also inform when you look at what's actually mediating the effect and probably something around inflammation is important